Why the study?
Does a new enzyme immunoassay using anti-MtCK monoclonal antibodies improve the accuracy of CK-MB activity measurement compared to conventional methods in human serum?
Does a new enzyme immunoassay using anti-MtCK monoclonal antibodies improve the accuracy of CK-MB activity measurement compared to conventional methods in human serum?
Answers are grounded in this paper and cite their sources.
A novel enzyme immunoassay using anti-MtCK monoclonal antibodies improves the accuracy of true CK-MB measurement by inhibiting mitochondrial creatine kinase activity.
Objective: The MB fraction of creatine kinase (CK-MB) has long been used as a cardiac marker. It is known that the CK-MB immunoinhibition method lacks selectivity and accuracy, because the appearance of macro CK type 2, corresponding to mitochondrial creatine kinase (MtCK) in some patient serum may render CK-MB activity measured by conventional method abnormally high. Thus, to improve the specificity and accuracy of the CK-MB assay, we developed two types of monoclonal anti-MtCK antibodies against sarcomeric MtCK and ubiquitous MtCK, and present herein the performance of a new method using these antibodies. Material and methods: The performance of our test for detecting CK-MB activity was compared with other methods, and the range of CK-MB activities in normal human serum was investigated. Results: The two types of monoclonal antibodies developed by us were isoenzyme-specific to sMtCK or uMtCK. The correlation coefficients of our method and conventional method to electrophoresis were 0.973 and 0.873, respectively. The mean CK-MB activity in normal human serum by our method and the conventional method was 2.4 and 11.7 U/L, respectively. Thus, our data indicated that about 80% of CK-MB activity, determined using the conventional method, seems to correspond to the MtCK activity. Conclusion: Our method is novel in offering higher accuracy of measuring true CK-MB contents in human serum as compared to the conventional method. The possibility of accurately estimating CK-MB activity by our method which can inhibit MtCKs in healthy person and patient serum is likely to bring a break-through in clinical diagnostics.
No takes yet. Share an insight, caveat, or question.
Hoshino et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: